International Journal of Hypertension

Research Article

Association of Antihypertensive Drug-Related Gene Polymorphisms with Stroke in the Chinese Hypertensive Population

Table 4

Association between antihypertensive drug-related genes polymorphism and stroke occurrence in hypertensive patients (controls = 28846 and stroke = 816).


Gene loci	Crude OR (95% CI)	Adjusted OR^‡ (95% CI)	Adjusted OR^§ (95% CI)

ADRB1 (1165G > C)
CC	1.197 (1.039–1.380)	1.186 (1.029–1.368)	1.184 (1.026–1.365)
GC + GG	1^†	1^†	1^†
GG	1.119 (0.857–1.461)	1.186 (1.029–1.370)	1.099 (0.840–1.438)
GC + CC	1^†	1^†	1^†

CYP2D610
10/10	1.131 (0.980–1.305)	1.119 (0.969–1.292)	1.115 (0.966–1.288)
1/1+1/10	1^†	1^†	1^†
1/1	0.984 (0.829–1.168)	0.982 (0.827–1.166)	0.981 (0.825–1.166)
1/10+10/10	1^†	1^†	1^†

CYP2C93
1/1	1.063 (0.821–1.377)	1.033 (0.796–1.339)	1.021 (0.787–1.324)
1/3+3/3	1^†	1^†	1^†
3/3	Not available	Not available	Not available
1/3+1/1	1^†	1^†	1^†

AGTR1 (1166A > C)
1166A/A	1.133 (0.896–1.433)	1.115 (0.881–1.412)	1.122 (0.885–1.421)
1166A/C+1166C/C	1^†	1^†	1^†
1166C/C	1.207 (0.533–2.730)	1.293 (0.569–2.937)	1.279 (0.562–2.911)
1166A/C+1166A/A	1^†	1^†	1^†

ACE (I/D)
II	1.057 (0.920–1.215)	1.077 (0.936–1.239)	1.078 (0.937–1.240)
ID + DD	1^†	1^†	1^†
DD	0.945 (0.748–1.194)	0.921 (0.728–1.165)	0.923 (0.729–1.168)
ID + II	1^†	1^†	1^†

CYP3A53
3/3	0.921 (0.801–1.059)	0.936 (0.814–1.077)	0.938 (0.815–1.079)
1/3+1/1	1^†	1^†	1^†
1/1	1.096 (0.871–1.381)	1.072 (0.850–1.351)	1.080 (0.856–1.362)
1/3+3/3	1^†	1^†	1^†

NPPA (2238T > C)
TT	0.979 (0.593–1.617)	0.973 (0.587–1.612)	0.962 (0.580–1.595)
TC + CC	1^†	1^†	1^†
CC	0.855 (0.271–2.692)	0.942 (0.296–2.994)	0.946 (0.297–3.010)
TC + TT	1^†	1^†	1^†

. ^†Reference. ^‡Adjusted for age, sex, BMI, type of usual residence, education, marital status, control of SBP, control of DBP, presence of diabetes, presence of coronary heart disease, presence of COPD, presence of tumor, and family history related to hypertension, stroke, diabetes as covariates. ^§Adjusted for age, sex, BMI, type of usual residence, education, marital status, control of SBP, control of DBP, presence of diabetes, presence of coronary heart disease, presence of COPD, presence of tumor, family history related to hypertension, stroke, diabetes, and whether taking BBs, ACEIs, ARBs, CCBs, and diuretics as covariates.